Investments
192Portfolio Exits
44Funds
1Partners & Customers
1About Pfizer Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, Strategy, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline.
Want to inform investors similar to Pfizer Venture Investments about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Pfizer Venture Investments
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Pfizer Venture Investments in 1 Expert Collection, including Fortune 500 Investor list.
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Research containing Pfizer Venture Investments
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Pfizer Venture Investments in 1 CB Insights research brief, most recently on Jan 19, 2021.
Jan 19, 2021
27 Corporate Innovation Labs In HealthcareLatest Pfizer Venture Investments News
Sep 19, 2023
Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The round was co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture, with participation from another new investor that is a U.S.-based life sciences-focused fund as well as existing investors Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
Pfizer Venture Investments Investments
192 Investments
Pfizer Venture Investments has made 192 investments. Their latest investment was in Nimbus Therapeutics as part of their Series G on September 9, 2023.
Pfizer Venture Investments Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/6/2023 | Series G | Nimbus Therapeutics | $210M | No | 2 | |
6/7/2023 | Series A - II | Mozart Therapeutics | $25M | Yes | 8 | |
4/12/2023 | Series A | Crossbow Therapeutics | $80M | Yes | 4 | |
3/22/2023 | Series B | |||||
3/15/2023 | Series A - II |
Date | 9/6/2023 | 6/7/2023 | 4/12/2023 | 3/22/2023 | 3/15/2023 |
|---|---|---|---|---|---|
Round | Series G | Series A - II | Series A | Series B | Series A - II |
Company | Nimbus Therapeutics | Mozart Therapeutics | Crossbow Therapeutics | ||
Amount | $210M | $25M | $80M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 8 | 4 |
Pfizer Venture Investments Portfolio Exits
44 Portfolio Exits
Pfizer Venture Investments has 44 portfolio exits. Their latest portfolio exit was Pyxis Oncology on October 08, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/8/2021 | IPO | Public | 9 | ||
7/20/2021 | Acq - Fin | 1 | |||
6/15/2021 | Acquired | 1 | |||
Date | 10/8/2021 | 7/20/2021 | 6/15/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acq - Fin | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 9 | 1 | 1 |
Pfizer Venture Investments Acquisitions
1 Acquisition
Pfizer Venture Investments acquired 1 company. Their latest acquisition was Saama Technologies on October 20, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/20/2021 | Debt | $79.25M | Acq - Fin | 14 |
Date | 10/20/2021 |
|---|---|
Investment Stage | Debt |
Companies | |
Valuation | |
Total Funding | $79.25M |
Note | Acq - Fin |
Sources | 14 |
Pfizer Venture Investments Fund History
1 Fund History
Pfizer Venture Investments has 1 fund, including Pfizer Venture Investments.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/6/2018 | Pfizer Venture Investments | $600M | 2 |
Closing Date | 6/6/2018 |
|---|---|
Fund | Pfizer Venture Investments |
Fund Type | |
Status | |
Amount | $600M |
Sources | 2 |
Pfizer Venture Investments Partners & Customers
1 Partners and customers
Pfizer Venture Investments has 1 strategic partners and customers. Pfizer Venture Investments recently partnered with Nodality on August 8, 2012.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
8/9/2012 | Partner | United States | Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting . | 2 |
Date | 8/9/2012 |
|---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting . |
Sources | 2 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
